Skip to content

AnaptysBio, Inc. ANAB Free cash flow margin

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
24.6%-2.9pp
Eli Lilly logo
Eli LillyLLY
16.4%+8.7pp
Pfizer logo
PfizerPFE
18%+8.8pp
Amgen logo
AmgenAMGN
23.1%-8.9pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
27.6%+5.5pp
Biogen logo
BiogenBIIB
24.4%-0.4pp

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

Based on trailing twelve months.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s free cash flow margin?
AnaptysBio, Inc. (ANAB) reported free cash flow margin of 1.9% in Q1 2026.
How has AnaptysBio, Inc.'s free cash flow margin changed year-over-year?
AnaptysBio, Inc.'s free cash flow margin increased by 101.9% year-over-year, from -97.6% to 1.9%.
What is the long-term trend for AnaptysBio, Inc.'s free cash flow margin?
Over 3 years (2022 to 2025), AnaptysBio, Inc.'s free cash flow margin has grown at a -77.3% compound annual growth rate (CAGR), from -718.9% to 8.4%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.